美沙拉嗪缓释颗粒治疗溃疡性结肠炎30例疗效观察

Effect of Masalazine Delayed-release Granules in the Treatment of Ulcerative Colitis:Observation on 30 Cases

为观察美沙拉嗉缓释颗粒口服治疗溃疡性结肠炎的临床效果,将60例溃疡性结肠炎患者随机分为观察组和对照组,每组30例。观察组采用口服美沙拉嗪缓释颗粒治疗,对照组采用口服培菲康治疗,对比2组治疗效果、血清炎症因子情况及不良反应发生情况。结果显示,观察组总有效率为90.0%,对照组总有效率为66.7%,观察组总有效率高于对照组(P<0.05)。观察组TNF-α为(20.54±3.58)ng/mL、IL-17为(235.87±40.53)pg/mlL,对照组TNF-α为(26.98±3.33)ng/mL、IL-17为(320.57±45.55)pg/mL,观察组TNF-α和IL-17水平均低于对照组(P<0.05);观察组IL-10为(69.87±5.54)pg/mL,对照组IL-10为(58.74±5.23)pg/ml。,观察组IL-10水平高于对照组(P<0.05)。观察组不良反应发生率为6.7%,对照组为33.3%,2组比较差异有统计学意义(P<0.05)。结果表明,美沙拉嗉缓释颗粒治疗溃疡性结肠炎效果显著,值得临床推广应用。

To observe the clinical effect of mesalazine delayed release granules for treating ulcerative colitis （UC）,60 cases of UC were randomly divided into observation group （n = 30,orally administered this granules） and control one（ n = 30, received oral Bifico）, both groups＇ effect, serum inflammatory factors level change, and adverse reaction status were compared. As results, in observation group total effective rate ; the level of TNF-α, and IL-17 ; and the level of IL-10 were respectively higher, lower, and higher than those in control one[90.0% vs 66.7%, P 〈0.05;（20.54±3.58） ng/mL vs （26.98±3.33） ng/mL,and （235.87±40.53） pg/mL vs （320.57±45.55） pg/mL, P 〈0.05;and （69.87±5.54）pg/mL vs （58.74±5.23） pg/mL, P 〈0.05];besides, the adverse reaction incidence of observation group was significantly lower than that of control group（6.7 % vs 33.3 %, P 〈0.05）, there was statistical difference significance between the two groups. Results show that above-mentioned granules has significant effect on UC. It is worthy of clinical popularization and application.